1. Scrip

Cerevel Makes Progress, But Karuna Still One To Watch In Schizophrenia

Neuroscience Renaissance Continues

 
• By Andrew McConaghie

Competition to bring new schizophrenia therapies to market is increasing, with the need to demonstrate side-effect improvements over existing drugs especially important.

Mental health
Schizophrenia has not seen significant advances in treatment over the last 20 years. • Source: Alamy

Interest in the schizophrenia field is hotting up, with a recent readout from Cerevel Therapeutics and its candidate CVL-231 further bolstering belief that new therapies are around the corner after many years without significant advances.

Shares in Cerevel shot up on its Phase Ib results, but the firm is some way behind Karuna Therapeutics and its similar muscarinic receptor-targeting candidate which is already in Phase III

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas